Grant of Interim Extension of the Term of U.S. Patent No. 5,808,146; fluciclovine (18, 73168-73169 [2015-29887]
Download as PDF
<![CDATA[
73168
Federal Register / Vol. 80, No. 226 / Tuesday, November 24, 2015 / Notices
to apply. ITA expects to issue the results
of this process in April 2016.
Legal Authority: The statutory program
authority for ITA to conduct the IBP is 15
U.S.C. 4724. ITA has the legal authority to
enter into MOAs with show organizers under
the provisions of the Mutual Educational and
Cultural Exchange Act of 1961 (MECEA), as
amended (22 U.S.C.s 2455(f) and 2458(c)).
MECEA allows ITA to accept contributions of
funds and services from firms for the
purposes of furthering its mission.
The Office of Management and Budget
(OMB) has approved the information
collection requirements of the
application to this program (0625–0143)
under the provisions of the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501
et seq.) (OMB Control No. 0625–0143).
Notwithstanding any other provision of
law, no person is required to respond to,
nor shall a person be subject to a
penalty for failure to comply with, a
collection of information subject to the
requirements of the Paperwork
Reduction Act, unless that collection of
information displays a currently valid
OMB Control Number.
For further information please
contact: Vidya Desai, Acting Director,
International Buyer Program
(IBP2017@trade.gov).
Frank Spector,
Acting Director, Trade Promotion Programs.
[FR Doc. 2015–29858 Filed 11–23–15; 8:45 am]
BILLING CODE P
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
Pacific Fishery Management Council;
Public Meeting
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Notice of a public workshop.
AGENCY:
The Pacific Fishery
Management Council (Council) and the
NMFS Northwest and Southwest
Fisheries Science Centers (NWFSC and
SWFSC, respectively) will hold a public
workshop to review and critique its
groundfish stock assessment process in
2015. The Groundfish Stock Assessment
Process Review Workshop is open to the
public.
DATES: The Groundfish Stock
Assessment Process Review Workshop
will commence at 8:30 a.m. PT,
Wednesday, December 9, 2015 and
continue until 5:30 p.m. or as necessary
to complete business for the day. The
workshop will reconvene at 8:30 a.m.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:20 Nov 23, 2015
Jkt 238001
PT, Thursday, December 10, 2015 and
continue until 5:30 p.m. or as necessary
to complete business for the day
The Groundfish Stock
Assessment Process Review Workshop
will be held at Room 203, Fishery
Sciences Building (FSH), University of
Washington, 1122 NE Boat Street,
Seattle, WA 98105.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Mr.
John DeVore, Pacific Council;
telephone: (503) 820–2413.
The
purpose of the Groundfish Stock
Assessment Process Review Workshop
webinar is for participants in the
Council’s 2015 stock assessment process
to consider the procedures used in 2015
to assess and update groundfish stock
abundance and develop
recommendations for improving the
process for future assessments and
future assessment reviews. No
management actions will be decided in
this workshop. Any recommendations
developed at the workshop will be
submitted for consideration by the
Council at its March 2016 meeting in
Sacramento, CA or its April 2016
meeting in Vancouver, WA (see the
Council’s Web site at www.pcouncil.org
for future Council meeting agendas).
Although non-emergency issues not
identified in the workshop agenda may
come before the workshop participants
for discussion, those issues may not be
the subject of formal action during this
workshop. Formal action at the
workshop will be restricted to those
issues specifically listed in this notice
and any issues arising after publication
of this notice that require emergency
action under Section 305(c) of the
Magnuson Stevens Fishery Conservation
and Management Act, provided the
public has been notified of the
workshop participants’ intent to take
final action to address the emergency.
SUPPLEMENTARY INFORMATION:
Special Accommodations
This workshop is physically
accessible to people with disabilities.
Requests for sign language
interpretation or other auxiliary aids
should be directed to Mr. Kris
Kleinschmidt at (503) 820–2425 at least
5 days prior to the workshop date.
Dated: November 19, 2015.
Tracey L. Thompson,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2015–29891 Filed 11–23–15; 8:45 am]
BILLING CODE 3510–22–P
PO 00000
Frm 00007
Fmt 4703
Sfmt 4703
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No.: PTO–P–2015–0075]
Grant of Interim Extension of the Term
of U.S. Patent No. 5,808,146;
fluciclovine (18F)
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting interim extension under 35
U.S.C. 156(d)(5) for a one-year interim
extension of the term of U.S. Patent No.
5,808,146.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755; or by email to
Mary.Till@uspto.gov.
SUMMARY:
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On October 22, 2015, Emory
University, the patent owner of record,
timely filed an application under 35
U.S.C. 156(d)(5) for an interim extension
of the term of U.S. Patent No. 5,808,146.
The patent claims the active ingredient
fluciclovine (18F) of the drug product
AxuminTM. The application for patent
term extension indicates that New Drug
Application (NDA) 208054 was
submitted to the Food and Drug
Administration (FDA) on September 28,
2015. In a letter dated October 8, 2015,
FDA acknowledged receipt of NDA
208054 for ‘‘AxuminTM ([F–18]
Fluciclovine)’’.
Review of the patent term extension
application indicates that, except for
permission to market or use the product
commercially, the subject patent would
be eligible for an extension of the patent
term under 35 U.S.C. 156, and that the
patent should be extended for one year
as required by 35 U.S.C. 156(d)(5)(B).
Because the regulatory review period
SUPPLEMENTARY INFORMATION:
E:\FR\FM\24NON1.SGM
24NON1
Federal Register / Vol. 80, No. 226 / Tuesday, November 24, 2015 / Notices
has continued beyond the original
expiration date of the patent, November
9, 2015, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
5,808,146 is granted for a period of one
year from the original expiration date of
the patent.
Dated: November 18, 2015.
Robert Bahr,
Acting Deputy Commissioner for Patent
Examination Policy, United States Patent and
Trademark Office.
[FR Doc. 2015–29887 Filed 11–23–15; 8:45 am]
BILLING CODE 3510–16–P
BUREAU OF CONSUMER FINANCIAL
PROTECTION
[Docket No: CFPB–2015–0051]
Agency Information Collection
Activities: Comment Request
Bureau of Consumer Financial
Protection.
ACTION: Notice and request for comment.
AGENCY:
In accordance with the
Paperwork Reduction Act of 1995
(PRA), the Consumer Financial
Protection Bureau (Bureau) is requesting
to renew the Office of Management and
Budget (OMB) titled, ‘‘Report of Terms
of Credit Card Plans (FR 2572)’’.
DATES: Written comments are
encouraged and must be received on or
before January 25, 2016 to be assured of
consideration.
ADDRESSES: You may submit comments,
identified by the title of the information
collection, OMB Control Number (see
below), and docket number (see above),
by any of the following methods:
• Electronic: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Consumer Financial
Protection Bureau (Attention: PRA
Office), 1700 G Street NW., Washington,
DC 20552.
• Hand Delivery/Courier: Consumer
Financial Protection Bureau (Attention:
PRA Office), 1275 First Street NE.,
Washington, DC 20002.
Please note that comments submitted
after the comment period will not be
accepted. In general, all comments
received will become public records,
including any personal information
provided. Sensitive personal
information, such as account numbers
or social security numbers, should not
be included.
FOR FURTHER INFORMATION CONTACT:
Documentation prepared in support of
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:20 Nov 23, 2015
Jkt 238001
this information collection request is
available at www.regulations.gov.
Requests for additional information
should be directed to the Consumer
Financial Protection Bureau, (Attention:
PRA Office), 1700 G Street NW.,
Washington, DC 20552, (202) 435–9575,
or email: PRA@cfpb.gov. Please do not
submit comments to this mailbox.
SUPPLEMENTARY INFORMATION:
Title of Collection: Report of Terms of
Credit Card Plans (FR 2572).
OMB Control Number: 3170–0001.
Type of Review: Extension without
change of a currently approved
collection.
Affected Public: Private Sector.
Estimated Number of Respondents:
150.
Estimated Total Annual Burden
Hours: 75.
Abstract: Form FR 2572 collects data
on credit card pricing and availability
from a sample of at least 150 financial
institutions that offer credit cards. The
data enable the Consumer Financial
Protection Bureau (CFPB or the Bureau)
to present information to the public on
terms of credit card plans.
Request for Comments: Comments are
invited on: (a) Whether the collection of
information is necessary for the proper
performance of the functions of the
Bureau, including whether the
information will have practical utility;
(b) The accuracy of the Bureau’s
estimate of the burden of the collection
of information, including the validity of
the methods and the assumptions used;
(c) Ways to enhance the quality, utility,
and clarity of the information to be
collected; and (d) Ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Comments submitted in
response to this notice will be
summarized and/or included in the
request for OMB approval. All
comments will become a matter of
public record.
Dated: November 17, 2015.
Darrin A. King,
Paperwork Reduction Act Officer, Bureau of
Consumer Financial Protection.
[FR Doc. 2015–29818 Filed 11–23–15; 8:45 am]
BILLING CODE 4810–AM–P
BUREAU OF CONSUMER FINANCIAL
PROTECTION
[Docket No: CFPB–2015–0048]
Agency Information Collection
Activities: Comment Request
Bureau of Consumer Financial
Protection.
AGENCY:
PO 00000
Frm 00008
Fmt 4703
Sfmt 4703
ACTION:
73169
Notice and request for comment.
In accordance with the
Paperwork Reduction Act of 1995
(PRA), the Consumer Financial
Protection Bureau (Bureau) is proposing
a new information collection titled,
‘‘Financial Well-Being National
Survey.’’
SUMMARY:
Written comments are
encouraged and must be received on or
before January 25, 2016 to be assured of
consideration.
ADDRESSES: You may submit comments,
identified by the title of the information
collection, OMB Control Number (see
below), and docket number (see above),
by any of the following methods:
• Electronic: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Consumer Financial
Protection Bureau (Attention: PRA
Office), 1700 G Street NW., Washington,
DC 20552.
• Hand Delivery/Courier: Consumer
Financial Protection Bureau (Attention:
PRA Office), 1275 First Street NE.,
Washington, DC 20002.
Please note that comments submitted
after the comment period will not be
accepted. In general, all comments
received will become public records,
including any personal information
provided. Sensitive personal
information, such as account numbers
or social security numbers, should not
be included.
FOR FURTHER INFORMATION CONTACT:
Documentation prepared in support of
this information collection request is
available at www.regulations.gov.
Requests for additional information
should be directed to the Consumer
Financial Protection Bureau, (Attention:
PRA Office), 1700 G Street NW.,
Washington, DC 20552, (202) 435–9575,
or email: PRA@cfpb.gov. Please do not
submit comments to this mailbox.
SUPPLEMENTARY INFORMATION:
Title of Collection: Financial WellBeing National Survey.
OMB Control Number: 3170–XXXX.
Type of Review: New collection
(Request for a new OMB control
number).
Affected Public: Individuals.
Estimated Number of Respondents:
6,000.
Estimated Total Annual Burden
Hours: 2,000.
Abstract: Under the Dodd-Frank Wall
Street Reform and Consumer Protection
Act, Public Law 111–203, the Bureau’s
Office of Financial Education is
responsible for developing and
implementing a strategy to improve the
financial literacy of consumers that
DATES:
E:\FR\FM\24NON1.SGM
24NON1
]]>Agencies
[Federal Register Volume 80, Number 226 (Tuesday, November 24, 2015)]
[Notices]
[Pages 73168-73169]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-29887]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
[Docket No.: PTO-P-2015-0075]
Grant of Interim Extension of the Term of U.S. Patent No.
5,808,146; fluciclovine (\18\F)
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term Extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension under 35 U.S.C. 156(d)(5) for a one-
year interim extension of the term of U.S. Patent No. 5,808,146.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On October 22, 2015, Emory University, the patent owner of record,
timely filed an application under 35 U.S.C. 156(d)(5) for an interim
extension of the term of U.S. Patent No. 5,808,146. The patent claims
the active ingredient fluciclovine (\18\F) of the drug product
AxuminTM. The application for patent term extension
indicates that New Drug Application (NDA) 208054 was submitted to the
Food and Drug Administration (FDA) on September 28, 2015. In a letter
dated October 8, 2015, FDA acknowledged receipt of NDA 208054 for
``AxuminTM ([F-18] Fluciclovine)''.
Review of the patent term extension application indicates that,
except for permission to market or use the product commercially, the
subject patent would be eligible for an extension of the patent term
under 35 U.S.C. 156, and that the patent should be extended for one
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory
review period
[[Page 73169]]
has continued beyond the original expiration date of the patent,
November 9, 2015, interim extension of the patent term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 5,808,146 is granted for a period of one year from the
original expiration date of the patent.
Dated: November 18, 2015.
Robert Bahr,
Acting Deputy Commissioner for Patent Examination Policy, United States
Patent and Trademark Office.
[FR Doc. 2015-29887 Filed 11-23-15; 8:45 am]
BILLING CODE 3510-16-P
